Chrome Plugin Live! Redefine the way you read FinTwit š Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
MNPR
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-0.95
vsĀ -0.95
Q2.23
N/A
-0.80
vsĀ -1.10
Q3.23
N/A
-0.70
vsĀ -0.95
Q4.23
N/A
-0.60
vsĀ -1.10
Q1.24
N/A
-0.50
vsĀ -0.95
Q2.24
N/A
-0.50
vsĀ -0.80
Q3.24
N/A
-0.37
vsĀ -0.70
Q4.24
N/A
-2.23
vsĀ -0.60
Q1.25
N/A
-0.55
vsĀ -0.50
Q2.25
N/A
-0.46
vsĀ -0.50
Sales Growth
YoY
Current
Estimates
Q3.22
NA
NAĀ vsĀ NA
Q4.22
NA
NAĀ vsĀ NA
Q1.23
NA
NAĀ vsĀ NA
Q2.23
NA
NAĀ vsĀ NA
Q3.23
NA
NAĀ vsĀ NA
Q4.23
NA
NAĀ vsĀ NA
Q1.24
NA
NAĀ vsĀ NA
Q2.24
NA
NAĀ vsĀ NA
Q3.24
NA
NAĀ vsĀ NA
Q4.24
NA
NAĀ vsĀ NA
Return on Equity
QoQ
Q1.23
-26%
-0.26
vsĀ -0.29
Q2.23
-28%
-0.28
vsĀ -0.26
Q3.23
-30%
-0.30
vsĀ -0.28
Q4.23
-32%
-0.32
vsĀ -0.30
Q1.24
-22%
-0.22
vsĀ -0.32
Q2.24
-28%
-0.28
vsĀ -0.22
Q3.24
-26366%
-263.66
vsĀ -0.28
Q4.24
-20%
-0.20
vsĀ -263.66
Institutionnal Ownership
QoQ
Q3.22
8
8
vsĀ 10
-20%
Q4.22
10
10
vsĀ 8
25%
Q1.23
11
11
vsĀ 10
10%
Q2.23
8
8
vsĀ 11
-27%
Q3.23
14
14
vsĀ 8
75%
Q4.23
14
14
vsĀ 14
NA
Q1.24
15
15
vsĀ 14
7%
Q2.24
12
12
vsĀ 15
-20%
Forecast
-623%2025-EPS
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
Piper Sandler
initialisePrevious: Not converted
2025-01-10
Now: Overweight
Rodman & Renshaw
initialisePrevious: Not converted
2024-10-11
Now: Buy
Roth Capital
initialisePrevious: Not converted
2021-01-28
Now: Buy
globenewswire.com
8 hours ago
zacks.com
9 hours ago
zacks.com
11 hours ago
zacks.com
11 hours ago
prnewswire.com
13 hours ago
seekingalpha.com
14 hours ago
Quote Panel
Key Metrics
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo EspaƱol de InvestigaciĆ³n en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
NASDAQ
Unprofitable
Unprofitable
-1.86Ā ( -4.17%)
Relative Strenght
99
Volume Buzz
-61%
Earning Acce
No
Dist 52w H.
21%Relative Strength
MNPR
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|